A Phase I Study Assessing the Safety, Tolerability and Pharmacokinetics of AZD1775 in Combination With MEDI4736 in Patients With Advanced Solid Tumours
Phase of Trial: Phase I
Latest Information Update: 18 Apr 2018
At a glance
- Drugs Adavosertib (Primary) ; Durvalumab
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors AstraZeneca
- 10 Apr 2018 Treatment table changed to have 4 dosing schedules, study design changed from single group assignment to parallel group assignment.
- 05 Jan 2018 Planned End Date changed from 21 Mar 2018 to 15 Oct 2018.
- 05 Jan 2018 Planned primary completion date changed from 21 Mar 2018 to 15 Oct 2018.